Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
Isofol Medical AB (ISOFOL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.089x
Based on the latest financial reports, Isofol Medical AB (ISOFOL) has a cash flow conversion efficiency ratio of -0.089x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.78 Million) by net assets (Skr120.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Isofol Medical AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Isofol Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Isofol Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Isofol Medical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Painchek Ltd
AU:PCK
|
1.892x |
|
Ynvisible Interactive Inc
OTCQB:YNVYF
|
-0.605x |
|
FM Global Logistics Holdings Bhd
KLSE:7210
|
0.028x |
|
Champion Technology Holdings Ltd
PINK:CPIHF
|
-0.145x |
|
Earth Tech Environment Public Company Limited
BK:ETC
|
0.001x |
|
LGMS Berhad
KLSE:0249
|
0.039x |
|
Opter AB
ST:OPTER
|
0.230x |
|
Izotropic Corporation
OTCQB:IZOZF
|
0.062x |
Annual Cash Flow Conversion Efficiency for Isofol Medical AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Isofol Medical AB from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr107.87 Million | Skr-51.94 Million | -0.481x | +10.62% |
| 2024-12-31 | Skr77.94 Million | Skr-41.99 Million | -0.539x | -24.51% |
| 2023-12-31 | Skr121.43 Million | Skr-52.54 Million | -0.433x | +64.10% |
| 2022-12-31 | Skr158.48 Million | Skr-190.97 Million | -1.205x | -103.52% |
| 2021-12-31 | Skr318.23 Million | Skr-188.43 Million | -0.592x | +75.41% |
| 2020-12-31 | Skr66.57 Million | Skr-160.27 Million | -2.408x | -71.58% |
| 2019-12-31 | Skr104.91 Million | Skr-147.21 Million | -1.403x | -302.20% |
| 2018-12-31 | Skr265.01 Million | Skr-92.46 Million | -0.349x | -93.21% |
| 2017-12-31 | Skr343.03 Million | Skr-61.94 Million | -0.181x | +98.06% |
| 2016-12-31 | Skr6.10 Million | Skr-56.90 Million | -9.330x | +66.45% |
| 2015-12-31 | Skr1.32 Million | Skr-36.77 Million | -27.812x | -- |